Devyser Diagnostics 過去の業績

過去基準チェック /06

Devyser Diagnosticsの収益は年間平均-36%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 23.9%割合で増加しています。

主要情報

-36.0%

収益成長率

-31.8%

EPS成長率

Biotechs 業界の成長	0.7%
収益成長率	23.9%
株主資本利益率	-20.5%
ネット・マージン	-36.0%
次回の業績アップデート	13 Feb 2025

Recent updates

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Jun 14

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Mar 20

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Dec 09

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

Aug 30

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 14

収支内訳

Devyser Diagnostics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:DVYSR 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	198	-71	187	45
30 Jun 24	196	-54	178	45
31 Mar 24	181	-46	169	37
31 Dec 23	169	-54	164	38
30 Sep 23	158	-57	165	34
30 Jun 23	143	-60	157	31
31 Mar 23	136	-60	146	33
31 Dec 22	127	-46	132	26
30 Sep 22	117	-40	115	23
30 Jun 22	110	-35	103	22
31 Mar 22	101	-27	90	18
31 Dec 21	93	-21	76	18
31 Dec 20	66	-11	42	17
31 Dec 19	64	7	34	7
31 Dec 18	48	1	30	7

質の高い収益: DVYSRは現在利益が出ていません。

利益率の向上: DVYSRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: DVYSRは利益が出ておらず、過去 5 年間で損失は年間36%の割合で増加しています。

成長の加速: DVYSRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: DVYSRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: DVYSRは現在利益が出ていないため、自己資本利益率 ( -20.46% ) はマイナスです。

Devyser Diagnostics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings released: kr1.41 loss per share (vs kr0.90 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.75 loss per share (vs kr1.23 loss in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024

Recent updates

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 18%

Chief Executive Officer recently bought kr324k worth of stock

Second quarter 2024 earnings released: kr1.41 loss per share (vs kr0.90 loss in 2Q 2023)

New minor risk - Shareholder dilution

Chief Executive Officer recently sold kr5.5m worth of stock

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Devyser Diagnostics AB (publ) Appoints Thomas Eklund as Member of the Board of Directors

Chief Executive Officer recently bought kr299k worth of stock

First quarter 2024 earnings released: kr0.75 loss per share (vs kr1.23 loss in 1Q 2023)

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software

Full year 2023 earnings: EPS misses analyst expectations

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Consensus estimates of losses per share improve by 66%

Devyser Diagnostics AB (publ) Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Insider selling

Devyser Diagnostics AB (Publ) Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024

Devyser Diagnostics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Chief Executive Officer recently bought kr1.5m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024

Consensus estimates of losses per share improve by 29%

Independent Director recently bought kr1.1m worth of stock

Consensus revenue estimates fall by 11%

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Devyser's Ngs Products for Monitoring of Kidney and Stem Cell Transplanted Patients Receive IVDR Approvals

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Devyser Announces its Deputy CEO and Founder Ulf Klangby Moves to Advisory Role

Chief Executive Officer recently bought kr105k worth of stock

Devyser Diagnostics AB Announces Approval of Devyser's RHD Product in Canada

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to kr1.89 loss

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 1,989%

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.55 loss per share (vs kr0.87 loss in 3Q 2021)

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Devyser Diagnostics AB (publ) Appoints John Murad as Vice President and General Manager in the US

Consensus EPS estimates fall by 66%

Second quarter 2022 earnings released: kr0.90 loss per share (vs kr0.94 loss in 2Q 2021)

Devyser Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Devyser Diagnostics AB (Publ) Appoints Camilla Wiberg as Chief HR Officer

Less than half of directors are independent

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Devyser Diagnostics AB (publ), Annual General Meeting, May 11, 2022

Less than half of directors are independent

Devyser Diagnostics AB (publ) Appoints Theis Kipling as Chief Commercial Officer

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ) to Report Q4, 2021 Results on Feb 24, 2022

Devyser Diagnostics AB (publ) (OM:DVYSR) agreed to acquire the remaining 70.1% stake in Smartseq S.R.L. from its three founders for €0.84 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06